WHO Clears Rabies Vaccine Of India’s Zydus Cadila
This article was originally published in PharmAsia News
The World Health Organization has cleared India's Zydus Cadila to sell its Lyssavac rabies vaccine to United Nations agencies. The clearance makes Zydus, part of Zydus Cadila Group, the first Indian company approved for UN sales. Zydus markets the vaccine, produced in collaboration with Berna Biotech of Switzerland, in India as Vaxirab. Outside of India, the vaccine is available only in South Asia and Africa. (Click here for more
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.